CTLA4 and neoplasm: Anti-CTLA-4 treatment resulted in the eradication of tumors in four out of five mice (Figure 1a,b), whereas anti-PD-1 temporarily inhibited YTN16 tumor growth but failed to eradicate the tumor in four out of five mice.